Coherus BioSciences Reports First Quarter 2016 Financial and Operating Results
CHS-1420 (adalimumab biosimilar) Formulation Patents to Issue in May Completed Private Convertible Financing of $100 million Received $30 million Milestone Payment from Baxalta in May REDWOOD CITY, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Coherus …